tiprankstipranks
Trending News
More News >
Biotricity Inc (BTCY)
OTHER OTC:BTCY
US Market

Biotricity (BTCY) Earnings Dates, Call Summary & Reports

Compare
121 Followers

Earnings Data

Report Date
Jun 26, 2026
Before Open (Confirmed)
Period Ending
2026 (Q4)
Consensus EPS Forecast
Last Year’s EPS
-0.08
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2026
Earnings Call Date:Feb 11, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: double-digit revenue growth, meaningful gross margin expansion (+516 bps), consecutive positive EBITDA quarters (3) and six consecutive quarters of positive free cash flow, plus strong digital user and provider network expansion. Remaining challenges include a continued net loss ($1.1M), modest absolute revenue scale ($4.0M quarterly), concentration of revenue in technology fees (91.2%), and dependence on future FDA/regulatory clearances and large-account sales cycles. Overall, the positives (margin improvement, recurring revenue, cash-flow and EBITDA momentum, product traction and distribution reach) outweigh the remaining execution and scale risks.
Company Guidance
In the Q3 FY2026 call (period ended Dec. 31, 2025) management guided to continued top-line growth and a shift to profitability in calendar 2026—expecting to turn net‑income positive this year—citing Q3 revenue of $4.0M (up 10.2% vs. $3.6M), technology fees at 91.2% of revenue, gross profit $3.3M (+17.6% YoY) and gross margin 81.5% (up 516 bps from 76.4%), operating expenses $2.8M (down 4.2% YoY) with SG&A down 8.2% (~$195K) and R&D up $72K, EBITDA of $280K ($0.01/share) marking three consecutive quarters of positive EBITDA and six consecutive quarters of positive free cash flow, a net loss of $1.1M (vs. $1.3M) and loss per share $0.042 (vs. $0.054); they also highlighted user growth from 4,500 to >44,000 in two years, >2,500 providers supporting ~400,000 patients annually, expanded Biocore Pro pilots, GPO access to >90% of U.S. hospitals, and stated additional margin and expense improvements are expected with upcoming FDA clearances and international approvals.
Revenue Growth
Total revenue for the quarter was $4.0M, up 10.2% year-over-year from $3.6M in the prior-year quarter.
Strong Gross Profit and Margin Expansion
Gross profit rose to $3.3M, up 17.6% year-over-year from $2.8M, and gross margin improved by 516 basis points to 81.5% from 76.4%, driven by a larger recurring technology fee base and efficiencies from AI and cloud/monitoring cost improvements.
Recurring Revenue Mix
Technology fees accounted for 91.2% of the quarter's total revenue, indicating strong market adoption and a recurring Technology-as-a-Service subscription model supported by usage-based subscriptions.
Profitability Momentum (EBITDA and Cash Flow)
Company achieved positive EBITDA of $280K (approximately $0.01 per share) and marked its third consecutive quarter of positive EBITDA; Biotricity has generated positive free cash flow (cash from operations available to pay interest and dividends) for six consecutive quarters.
Reduced Operating Costs
Operating expenses decreased 4.2% to $2.8M from $2.93M year-over-year; selling, general & administrative expenses fell 8.2 (a reduction of over $195K), demonstrating progress on cost management and sales-force transformation.
Product and Commercial Traction
Continued expansion and sales of Biocore Pro (next-generation cardiac monitor with cellular connectivity), multiple large-scale hospital and clinic pilot programs launched, and expectation of continued adoption across existing and new customers.
Digital Ecosystem and Clinical Reach
Digital health app users grew from 4,500 to more than 44,000 over two years (~+878%), the provider network expanded to over 2,500 providers supporting ~400,000 patients annually, and the company maintains contracts with three of the largest GPO networks providing access to >90% of U.S. hospitals.
Regulatory and International Progress
Pursuing FDA clearance for an AI clinical model and continuing regulatory approvals internationally (existing approvals in U.S., Canada, Saudi Arabia, Argentina and other smaller markets) to support future distribution.

Biotricity (BTCY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BTCY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jun 26, 2026
2026 (Q4)
- / -
-0.077
Feb 11, 2026
2026 (Q3)
- / -0.04
-0.05422.22% (+0.01)
Nov 14, 2025
2026 (Q2)
-0.08 / -0.03
-0.07358.90% (+0.04)
Aug 14, 2025
2026 (Q1)
- / 0.03
-0.075140.00% (+0.10)
Jul 17, 2025
2025 (Q4)
-0.09 / 0.01
-0.075117.33% (+0.09)
Feb 20, 2025
2025 (Q3)
-0.11 / -0.05
-0.33984.07% (+0.29)
Nov 15, 2024
2025 (Q2)
- / -0.07
-0.4483.41% (+0.37)
Aug 21, 2024
2025 (Q1)
- / -0.07
-0.4181.71% (+0.33)
Jun 27, 2024
2024 (Q4)
-0.36 / -0.47
-0.5616.07% (+0.09)
Feb 21, 2024
2024 (Q3)
-0.44 / -0.34
-0.5437.22% (+0.20)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BTCY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 11, 2026
$0.24$0.240.00%
Nov 14, 2025
$0.53$0.57+7.55%
Aug 14, 2025
$0.54$0.540.00%
Jul 17, 2025
$0.38$0.39+2.63%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biotricity Inc (BTCY) report earnings?
Biotricity Inc (BTCY) is schdueled to report earning on Jun 26, 2026, Before Open (Confirmed).
    What is Biotricity Inc (BTCY) earnings time?
    Biotricity Inc (BTCY) earnings time is at Jun 26, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BTCY EPS forecast?
          Currently, no data Available